 |
|
Current Diagnosis and Treatment in Rheumatology
By John Imboden, David Hellmann, and John Stone, 2nd ed, 528 pp, $64.95.
New York, NY, McGraw-Hill (Lange Medical Publications), 2007.
ISBN-13 978-0-0714-6040-8.
JAMA. 2007;298:463-465.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The current practice of rheumatology is a fascinating mix of slowly evolving changes in diagnoses and rapidly changing treatment protocols. Since the approval of the first biological therapy in 1998, these drugs have led to a revolution in the treatment of several rheumatologic diseases. Prior to the introduction of the biologics, methotrexate therapy, the gold-standard treatment, could induce remissions in perhaps 10% of patients with rheumatoid arthritis. The entire severity curve has now shifted toward less severe disease, and combination treatment with a biologic along with methotrexate can induce remissions in as many as 30% of patients. Biologics were recently approved for ankylosing spondylitis and psoriatic arthritis. Biologics are currently being used for lupus and other rheumatologic diseases. With any new therapies come new adverse effects. Therefore, a textbook must be up to date with the latest treatments and their adverse effects, as well as detailed enough to cover the . . . [Full Text of this Article]
Daniel Muller, MD, PhD, Reviewer
Section of Rheumatology
Curriculum Development
School of Medicine and Public Health
University of Wisconsin-Madison
dmuller@wisc.edu
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
CURRENT RHEUMATOLOGY DIAGNOSIS & TREATMENT, 2ND Edn, Edited by J. Imboden, D. Hellmann and J. Stone.
Khurshid
Rheumatology (Oxford) 2008;47:1262-1262.
FULL TEXT
|
